tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2021-99-9-6-14tiblj-1567Research ArticleОБЗОРREVIEWБронхиальная астма и COVID-19: вопросы коморбидностиBronchial Asthma and COVID-19: Comorbidity IssuesОвсянниковЕ. С.OvsyannikovE. S.

Овсянников Евгений Сергеевич, доктор медицинских наук, доцент кафедры факультетской терапии.394036, г. Воронеж, Студенческая ул., д. 10.Телефон: +7 (473) 263-81-30

Evgeny S. Ovsyannikov, Doctor of Medical Sciences, Associate Professor of Faculty Therapy Department

10, Studencheskaya St., Voronezh, 394036.Phone: +7 (473) 263-81-30

ovses@yandex.ruАвдеевС. Н.АvdeevS. N.

Авдеев Сергей Николаевич, доктор медицинских наук, член-корреспондент РАН, заведующий кафедрой пульмонологии лечебного факультета.119991, Москва, ул. Трубецкая, д. 8, стр. 2.Тел.: +7 (495) 708-35-76

Sergey N. Аvdeev, Doctor of Medical Sciences, Correspondent Member of RAS, Head of Pulmonology Department of General Medicine Faculty.8, Bd. 2, Trubetskaya St., Moscow, 119991.Phone: +7 (495) 708-35-76

serg_avdeev@list.ruБудневскийА. В.BudnevskiyA. V.

Будневский Андрей Валериевич, доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии.394036, г. Воронеж, Студенческая ул., д. 10.Телефон: +7 (473) 263-81-30

Andrey V. Budnevskiy, Doctor of Medical Sciences, Professor,Head of Faculty Therapy Department

10, Studencheskaya St., Voronezh, 394036.Phone: +7 (473) 263-81-30

budnev@list.ruДробышеваЕ. С.DrobyshevaE. S.

Дробышева Елена Сергеевна, кандидат медицинских наук, доцент кафедры факультетской терапии

394036, г. Воронеж, Студенческая ул., д. 10.Телефон: +7 (473) 263-81-30

Elena S. Drobysheva, Candidate of Medical Sciences,Associate Professor of Faculty Therapy Department

10, Studencheskaya St., Voronezh, 394036.Phone: +7 (473) 263-81-30

e.drobysheva76@mail.ruСавушкинаИ. А.SavushkinaI. A.

Савушкина Инесса Алексеевна, ординатор 2-го курса кафедры факультетской терапии.394036, г. Воронеж, Студенческая ул., д. 10.Телефон: +7 (473) 263-81-30

Inessa A. Savushkina, Resident of the 2nd Year of Trainingof Faculty Therapy Department

10, Studencheskaya St., Voronezh, 394036.Phone: +7 (473) 263-81-30

savushkinainessa@yandex.ruФГБОУ ВО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» МЗ РФРоссияVoronezh State Medical University named after N.N. BurdenkoRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФ (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202122092021999614Copyright © Овсянников Е.С., Авдеев С.Н., Будневский А.В., Дробышева Е.С., Савушкина И.А., 20212021Овсянников Е.С., Авдеев С.Н., Будневский А.В., Дробышева Е.С., Савушкина И.А.Ovsyannikov E.S., Аvdeev S.N., Budnevskiy A.V., Drobysheva E.S., Savushkina I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1567

В обзоре литературы приводятся результаты исследований, посвященных различным аспектам сочетания бронхиальной астмы и COVID-19. В частности, затрагиваются вопросы частоты встречаемости бронхиальной астмы среди пациентов с подтвержденным COVID-19, влияния бронхиальной астмы на риск развития новой коронавирусной инфекции, особенности течения бронхиальной астмы у пациентов с COVID-19. Рассматриваются особенности применения отдельных компонентов базисной терапии бронхиальной астмы в период пандемии, в частности ингаляционных и системных кортикостероидов, антилейкотриеновых препаратов, таргетной терапии. Уделяется внимание рекомендациям по выбору устройств для введения ингаляционных лекарственных препаратов в свете профилактики распространения новой коронавирусной инфекции.

This literature review presents findings on various aspects of concurrent bronchial asthma and COVID-19. In particular, it discusses issues of bronchial asthma incidence among patients with confirmed COVID-19, the influence of bronchial asthma on the risk of the new coronavirus infection, and the specific course of bronchial asthma in COVID-19 patients. It considers the use of individual components of basic asthma therapy during the pandemic, in particular, inhaled and systemic corticosteroids, antileukotriene drugs, and targeted therapy. The article pays attention to recommendations for the choice of inhalation devices in light of prevention of the new coronavirus infection spread.

бронхиальная астмаCOVID-19коморбидностьbronchial asthmaCOVID-19comorbidityReferencesГудима Г. О., Хаитов Р. М., Кудлай Д. А., Хаитов М. Р. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции // Иммунология. ‒ 2021. ‒ Т. 42, № 3. ‒ С. 198-210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.Gudima G.O., Khaitov R.M., Kudlay D.А., Khaitov M.R. Molecular immunological aspects of diagnosis, prevention and treatment of coronavirus infection. Immunologiya, 2021, vol. 42, no. 3, pp. 198-210. (In Russ.) doi: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.Ермолова А. В., Будневский А. В., Малыш Е. Ю., Овсянников Е. С., Дробышева Е. С. Бронхиальная астма и метаболический синдром // Клиническая медицина. – 2015. – Т. 93, № 6. – С. 44-49.Ermolova А.V., Budnevskiy А.V., Malysh E.Yu., Ovsyannikov E.S., Drobysheva E.S. Bronchial asthma and metabolic syndrome. Klinicheskaya Meditsina, 2015, vol. 93, no. 6, pp. 44-49. (In Russ.)Петров Д. В., Белевский А. С. Ведение пациентов с бронхиальной астмой в условиях пандемии COVID-19 // Астма и аллергия. – 2020. ‒ № 1. – С. 6-11.Petrov D.V., Belevskiy А.S. Management of patients with bronchial asthma in the COVID-19 pandemic. Astma I Allergiya, 2020, no. 1, pp. 6-11. (In Russ.)Провоторов В. М., Будневский А. В., Филатова Ю. И. Клинические проявления бронхиальной астмы под влиянием комплексной терапии с применением церулоплазмина // Терапевтический архив. – 2016. – Т. 88, № 3. – С. 36-39. DOI:10.17116/terarkh201688336-39.Provotorov V.M., Budnevskiy А.V., Filatova Yu.I. Clinical manifestations of bronchial asthma under the influence of complex therapy with ceruloplasmin. Terapevticheskiy Arkhiv, 2016, vol. 88, no. 3, pp. 36-39. (In Russ.) doi:10.17116/terarkh201688336-39.Провоторов В. М., Будневский А. В., Филатова Ю. И., Перфильева М. В. Антиоксидантная терапия при бронхиальной астме // Клиническая медицина. – 2015. – Т. 93, № 8. – С. 19-22.Provotorov V.M., Budnevskiy А.V., Filatova Yu.I., Perfilieva M.V. Antioxidant therapy in bronchial asthma. Klinicheskaya Meditsina, 2015, vol. 93, no. 8, pp. 19-22. (In Russ.)Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2019. https://spulmo.ru/upload/kr_bronhastma_2019.pdf Дата обращения 23.03.21.Rossiyskoe respiratornoe obschestvo. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu bronkhialnoy astmy. [Russian Respiratory Society. Federal clinical recommendations for diagnostics and treatment of bronchial asthma]. 2019. https://spulmo.ru/upload/kr_bronhastma_2019.pdf Accessed 23.03.21.Фомина Д. С., Сердотецкова С. А., Иванова М. С. и др. Ведение пациентов с COVID-19 и бронхиальной астмой: обзор литературы и клинический опыт авторов // Практическая пульмонология. – 2020. – № 2. – С. 3-15.Fomina D.S., Serdotetskova S.А., Ivanova M.S. et al. Management of patients with concurrent COVID-19 and bronchial asthma: literature review and clinical experience of the authors. Prakticheskaya Pulmonologiya, 2020, no. 2, pp. 3-15. (In Russ.)Хлудова Л. Г. Бронхиальная астма и COVID-19 // Астма и аллергия. – 2020. ‒ № 1. – С. 3-5.Khludova L.G. Bronchial asthma and COVID-19. Astma I Allergiya, 2020, no. 1, pp. 3-5. (In Russ.)Abrams E. M., Greenhawt M. Risk communication during COVID-19 // J. Allergy Clin. Immunol. Pract. – 2020. – Vol. 8, № 6. ‒ Р. 1791-1794. DOI: 10.1016/j.jaip.2020.04.012.Abrams E.M., Greenhawt M. Risk communication during COVID-19. J. Allergy Clin. Immunol. Pract., 2020, vol. 8, no. 6, pp. 1791-1794. doi: 10.1016/j.jaip.2020.04.012.Abrams E. M., Szefler S. J. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents // J. Pediatr. – 2020. – Vol. 222. – Р. 221-226. DOI: 10.1016/j.jpeds.2020.04.049.Abrams E.M., Szefler S.J. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents. J. Pediatr., 2020, vol. 222, pp. 221-226. doi: 10.1016/j.jpeds.2020.04.049.Amirav I., Newhouse M. T. Transmission of coronavirus by nebulizer: a serious, underappreciated risk // CMAJ. – 2020. – Vol. 192, № 13. – Е346. DOI: 10.1503/cmaj.75066.Amirav I., Newhouse M.T. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ, 2020, vol. 192, no. 13, Е346. doi: 10.1503/cmaj.75066.Arabi Y. M., Mandourah Y., Al-Hameed F. et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome // Am. J. Respir. Crit. Care Med. – 2018. – Vol. 197, № 6. – Р. 757-767. DOI: 10.1164/rccm.201706-1172OC.Arabi Y.M., Mandourah Y., Al-Hameed F. et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med., 2018, vol. 197, no. 6, pp. 757-767. doi: 10.1164/rccm.201706-1172OC.Ari A. Promoting safe and effective use of aerosol devices in COVID-19: risks and suggestions for viral transmission // Expert. Opin. Drug. Deliv. – 2020. – Vol. 17, № 11. – Р. 1509-1513. DOI: 10.1080/17425247.2020.1811225.Ari A. Promoting safe and effective use of aerosol devices in COVID-19: risks and suggestions for viral transmission. Expert. Opin. Drug. Deliv., 2020, vol. 17, no. 11, pp. 1509-1513. doi: 10.1080/17425247.2020.1811225.Avdeev S., Moiseev S., Brovko M. et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 // Allergy. ‒ 2020. ‒ Vol. 75, № 10. ‒ Р. 2703-2704. DOI: 10.1111/all.14420.Avdeev S., Moiseev S., Brovko M. et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy, 2020, vol. 75, no. 10, pp. 2703-2704. doi: 10.1111/all.14420.Bhatraju P. K., Ghassemieh B. J., Nichols M. et al. Covid-19 in critically ill patients in the Seattle region ‒ Case series // N. Engl. J. Med. – 2020. – Vol. 382, № 21. – Р. 2012-2022. DOI:10.1056/nejmoa2004500.Bhatraju P.K., Ghassemieh B.J., Nichols M. et al. Covid-19 in critically ill patients in the Seattle region ‒ Case series. N. Engl. J. Med., 2020, vol. 382, no. 21, pp. 2012-2022. doi:10.1056/nejmoa2004500.Bousquet J., Bergmann K. C., Zuberbier T., Bedbrook A., Onorato G. L., Jutel M., Akdis C. A., Akdis M., Klimek L., Pfaar O., Nadeau K. C., Chinthrajah S., Eiwegger T., Ansotegui I. J., Anto J. M., Bachert C., Bateman E. D., Bennoor K. S., Berghea E. C., Blain H. et al. ARIA-EAACI statement on Asthma and COVID-19 (JUNE 2, 2020) // Allergy. ‒ 2021. ‒ Vol. 76, № 3. ‒ Р. 689-697. DOI: 10.1111/all.14471.Bousquet J., Bergmann K.C., Zuberbier T., Bedbrook A., Onorato G.L., Jutel M., Akdis C.A., Akdis M., Klimek L., Pfaar O., Nadeau K.C., Chinthrajah S., Eiwegger T., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bennoor K.S., Berghea E.C., Blain H. et al. ARIA-EAACI statement on Asthma and COVID-19 (JUNE 2, 2020). Allergy, 2021, vol. 76, no. 3, pp. 689-697. doi: 10.1111/all.14471.Bozek A., Winterstein J. Montelukast’s ability to fight COVID-19 infection // J. Asthma. – 2020. – Р. 1-2. DOI:10.1080/02770903.2020.1786112.Bozek A., Winterstein J. Montelukast’s ability to fight COVID-19 infection. J. Asthma, 2020, pp. 1-2. doi:10.1080/02770903.2020.1786112.Brough H. A., Kalayci O., Sediva A. et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics ‒ The 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics // Pediatr. Allergy Immunol. – 2020. – Vol. 31, № 5. – Р. 442-448. DOI:10.1111/pai.13262.Brough H.A., Kalayci O., Sediva A. et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics ‒ The 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr. Allergy Immunol., 2020, vol. 31, no. 5, pp. 442-448. doi:10.1111/pai.13262.Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. – 2020. – Vol. 15, № 395. – Р. 507-513. DOI: 10.1016/S0140-6736(20)30211-7.Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, vol. 15, no. 395, pp. 507-513. doi: 10.1016/S0140-6736(20)30211-7.Chhiba K. D., Patel G. B., Vu T. H. T. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 // J. Allergy Clin. Immunol. – 2020. – Vol. 146, № 2. – Р. 307-314.e4. DOI:10.1016/j.jaci.2020.06.010.Chhiba K.D., Patel G.B., Vu T.H.T. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J. Allergy Clin. Immunol., 2020, vol. 146, no. 2, pp. 307-314.e4. doi:10.1016/j.jaci.2020.06.010.Chongmelaxme B., Lee S., Dhippayom T. et al. The effects of telemedicine on asthma control and patients’ quality of life in adults: a systematic review and meta-analysis // J. Allergy Clin. Immunol. Pract. – 2019. – Vol. 7, № 1. – Р. 199-216.e11. DOI: 10.1016/j.jaip.2018.07.015.Chongmelaxme B., Lee S., Dhippayom T. et al. The effects of telemedicine on asthma control and patients’ quality of life in adults: a systematic review and meta-analysis. J. Allergy Clin. Immunol. Pract., 2019, vol. 7, no. 1, pp. 199-216.e11. doi: 10.1016/j.jaip.2018.07.015.Chow N., Fleming-Dutra K., Gierke R. et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 ‒ United States, February 12 March 28, 2020 // MMWR Morb Mortal Wkly Rep. – 2020. – Vol. 69, № 13. – Р. 382-386. DOI:10.15585/mmwr.mm6913e2.Chow N., Fleming-Dutra K., Gierke R. et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 ‒ United States, February 12 March 28, 2020. MMWR Morb Mortal Wkly Rep., 2020, vol. 69, no. 13, pp. 382-386. doi:10.15585/mmwr.mm6913e2.Crimi C., Impellizzeri P., Campisi R. et al. Practical considerations for spirometry during the COVID-19 outbreak: literature review and insights // Pulmonology. – 2020. – S2531-0437(20)30175-6. DOI: 10.1016/j.pulmoe.2020.07.011.Crimi C., Impellizzeri P., Campisi R. et al. Practical considerations for spirometry during the COVID-19 outbreak: literature review and insights. Pulmonology, 2020, S2531-0437(20)30175-6. doi: 10.1016/j.pulmoe.2020.07.011.Dempsey O. Leukotriene receptor antagonist therapy // Postgrad Med. J. – 2000. – Vol. 76, № 902. – Р. 767-773.DOI :10.1136/pgmj.76.902.767.Dempsey O. Leukotriene receptor antagonist therapy. Postgrad Med. J., 2000, vol. 76, no. 902, pp. 767-773. doi :10.1136/pgmj.76.902.767.Docherty A. B., Harrison E. M., Green C. A. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort // BMJ. – 2020. – Vol. 369. m1985. DOI:10.1136/bmj.m1985.Docherty A.B., Harrison E.M., Green C.A. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort. BMJ, 2020, vol. 369. m1985. doi:10.1136/bmj.m1985.Dong X., Cao Y. Y., Lu X. X. et al. Eleven faces of coronavirus disease 2019 // Allergy. – 2020. – Vol. 75, № 7. – Р. 1699-1709. DOI: 10.1111/all.14289.Dong X., Cao Y.Y., Lu X.X. et al. Eleven faces of coronavirus disease 2019. Allergy, 2020, vol. 75, no. 7, pp. 1699-1709. doi: 10.1111/all.14289.Drummond M. Sleep labs, lung function tests and COVID-19 pandemic–only emergencies allowed! // Pulmonology. – 2020. – Vol. 26, № 4. – Р. 244-245. DOI: 10.1016/j.pulmoe.2020.04.002.Drummond M. Sleep labs, lung function tests and COVID-19 pandemic–only emergencies allowed! Pulmonology, 2020, vol. 26, no. 4, pp. 244-245. doi: 10.1016/j.pulmoe.2020.04.002.Du Y., Tu L., Zhu P. et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study // Am. J. Respir. Crit. Care Med. – 2020. – Vol. 201, № 11. – Р. 1372-1379. DOI: 10.1164/rccm.202003-0543OC.Du Y., Tu L., Zhu P. et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am. J. Respir. Crit. Care Med., 2020, vol. 201, no. 11, pp. 1372-1379. doi: 10.1164/rccm.202003-0543OC.Esquivel A., Busse W. W., Calatroni A. et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma // Am. J. Respir. Crit. Care Med. – 2017. – Vol. 196, № 8. – Р. 985-992. DOI: 10.1164/rccm.201701-0120OC.Esquivel A., Busse W.W., Calatroni A. et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am. J. Respir. Crit. Care Med., 2017, vol. 196, no. 8, pp. 985-992. doi: 10.1164/rccm.201701-0120OC.Ferastraoaru D., Hudes G., Jerschow E. et al. Eosinophilia in asthma patients is protective against severe COVID-19 illness // J. Allergy Clin. Immunol. Pract. – 2021. – Vol. 9, № 3. – Р. 1152-1162.e3. DOI: 10.1016/j.jaip.2020.12.045.Ferastraoaru D., Hudes G., Jerschow E. et al. Eosinophilia in asthma patients is protective against severe COVID-19 illness. J. Allergy Clin. Immunol. Pract., 2021, vol. 9, no. 3, pp. 1152-1162.e3. doi: 10.1016/j.jaip.2020.12.045.Garg S., Kim L., Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, March 1-30, 2020 // MMWR Morb Mortal Wkly Rep. – 2020. – Vol. 69, № 15. – Р. 458-464. DOI:1 0.15585/mmwr.mm6915e3.Garg S., Kim L., Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep., 2020, vol. 69, no. 15, pp. 458-464. doi:1 0.15585/mmwr.mm6915e3.Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (Accessed March 23, 2021).Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (Accessed March 23, 2021).Gosens R., Gross N. The mode of action of anticholinergics in asthma // Eur. Respir. J. – 2018. – Vol. 52, № 4. – Р. 701247. DOI: 10.1183/13993003.01247-2017.Gosens R., Gross N. The mode of action of anticholinergics in asthma. Eur. Respir. J., 2018, vol. 52, no. 4, pp. 701247. doi: 10.1183/13993003.01247-2017.Grandbastien M., Piotin A., Godet J. et al. SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation // J. Allergy Clin. Immunol. Pract. – 2020. – Vol. 8, № 8. – Р. 2600–2607. DOI: 10.1016/j.jaip.2020.06.032.Grandbastien M., Piotin A., Godet J. et al. SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation. J. Allergy Clin. Immunol., Pract., 2020, vol. 8, no. 8, pp. 2600-2607. doi: 10.1016/j.jaip.2020.06.032.Guan W. J., Ni Z. Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. – 2020. – Vol. 382, № 18. – Р. 1708-1720. DOI: 10.1056/NEJMoa2002032.Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, vol. 382, no. 18, pp. 1708-1720. doi: 10.1056/NEJMoa2002032.Halpin D. M, Singh D., Hadfield R. M. et.al. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective // Eur. Respir. Soc. – 2020. – Vol. 55, № 5. – Р. 2001009. DOI: 10.1183/13993003.01009-2020.Halpin D.M, Singh D., Hadfield R.M. et.al. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. Soc., 2020, vol. 55, no. 5, pp. 2001009, doi: 10.1183/13993003.01009-2020.Interim guidance about COVID-19 and asthma. Updated 20 Dec 2020. https://ginasthma.org/wp-content/uploads/2020/12/GINA-interim-guidance-on-COVID-19-and-asthma-20_12_20.pdf (Accessed March 20, 2021).Interim guidance about COVID-19 and asthma. Updated 20 Dec 2020. https://ginasthma.org/wp-content/uploads/2020/12/GINA-interim-guidance-on-COVID-19-and-asthma-20_12_20.pdf (Accessed March 20, 2021).Iwabuchi K., Yoshie K., Kurakami Y. et.al. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases // J. Infect. Chemother. – 2020. – Vol. 26, № 6. – Р. 625-632. DOI: 10.1016/j.jiac.2020.04.007.Iwabuchi K., Yoshie K., Kurakami Y. et.al. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases. J. Infect. Chemother., 2020, vol. 26, no. 6, pp. 625-632. doi: 10.1016/j.jiac.2020.04.007.Jackson D. J., Busse W. W., Bacharier L. B. et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 recepto2r ACE2 // J. Allergy Clin. Immunol. – 2020. – Vol. 46, № 1. – Р. 203-206.e3. DOI: 10.1016/j.jaci.2020.04.009.Jackson D.J., Busse W.W., Bacharier L.B. et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 recepto2r ACE2. J. Allergy Clin. Immunol., 2020, vol. 46, no. 1, pp. 203-206.e3. doi: 10.1016/j.jaci.2020.04.009.Khan A., Misdary C., Yegya-Raman N. et al. Montelukast in hospitalized patients diagnosed with COVID-19 // Research Square. – 2020. DOI:10.21203/rs.3.rs-52430/v1.Khan A., Misdary C., Yegya-Raman N. et al. Montelukast in hospitalized patients diagnosed with COVID-19. Research Square, 2020. doi:10.21203/rs.3.rs-52430/v1.Khan M., Khan M. N., Mustagir M. G. et al. Effects of pre-existing morbidities on occurrence of death among COVID-19 disease patients: a systematic review and meta-analysis // J. Global. Health. – 2020. – Vol. 10, № 2. – 020503. DOI:10.7189/jogh.10.020503.Khan M., Khan M.N., Mustagir M.G. et al. Effects of pre-existing morbidities on occurrence of death among COVID-19 disease patients: a systematic review and meta-analysis. J. Global. Health., 2020, vol. 10, no. 2, 020503. doi:10.7189/jogh.10.020503.Klimek L., Jutel M., Akdis C. et al. Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement // Allergy. – 2020. – Vol. 75, № 7. – Р. 1546-1554. DOI: 10.1111/all.14336.Klimek L., Jutel M., Akdis C. et al. Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement. Allergy, 2020, vol. 75, no. 7, pp. 1546-1554. doi: 10.1111/all.14336.Konopka K. E., Wilson A., Myers J. L. Postmortem lung findings in a patient with asthma and coronavirus disease 2019 // Chest. – 2020. – Vol. 158, № 3. – Р. e99-e101. DOI: 10.1016/j.chest.2020.04.032.Konopka K.E., Wilson A., Myers J.L. Postmortem lung findings in a patient with asthma and coronavirus disease 2019. Chest, 2020, vol. 158, no. 3, pp. e99-e101. doi: 10.1016/j.chest.2020.04.032.Kumar K., Hinks T. S. C., Singanayagam A. Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used? // Am. J. Physiol. Lung. Cell. Mol. Physiol. – 2020. – Vol. 318, № 6. – Р. L1244-L1247. DOI: 10.1152/ajplung.00144.2020.Kumar K., Hinks T.S.C., Singanayagam A. Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used? Am. J. Physiol. Lung. Cell. Mol. Physiol., 2020, vol. 318, no. 6, pp. L1244-L1247. doi: 10.1152/ajplung.00144.2020.Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan // J. Allergy Clin. Immunol. – 2020. – Vol. 146, № 1. – Р. 110-118. DOI: 10.1016/j.jaci.2020.04.006.Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. Allergy Clin. Immunol., 2020, vol. 146, no. 1, pp. 110-118. doi: 10.1016/j.jaci.2020.04.006.Licskai C., Yang C. L., Ducharme F. M. et al. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic // Can. J. Respir. Crit. Care Sleep. Med. – 2020. – Vol. 4, № 2. – Р. 73-76. DOI: 10.1080/24745332.2020.1754027.Licskai C., Yang C.L., Ducharme F.M. et al. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic. Can. J. Respir. Crit. Care Sleep. Med., 2020, vol. 4, no. 2, pp. 73-76. doi: 10.1080/24745332.2020.1754027.Lindsley A. W., Schwartz J. T., Rothenberg M. E. Eosinophil responses during COVID-19 infections and coronavirus vaccination // J. Allergy Clin. Immunol. – 2020. – Vol. 146, № 1. ‒ Р. 1-7. DOI: 10.1016/j.jaci.2020.04.021.Lindsley A.W., Schwartz J.T., Rothenberg M.E. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J. Allergy Clin. Immunol., 2020, vol. 146, no. 1, pp. 1-7. doi: 10.1016/j.jaci.2020.04.021.Liu S., Zhi Y., Ying S. COVID-19 and asthma: reflection during the pandemic // Clin. Rev. Allergy Immunol. – 2020. – Vol. 59, № 1. – Р. 78-88. DOI: 10.1007/s12016-020-08797-3.Liu S., Zhi Y., Ying S. COVID-19 and asthma: reflection during the pandemic. Clin. Rev. Allergy Immunol., 2020, vol. 59, no. 1, pp. 78-88. doi: 10.1007/s12016-020-08797-3.Matsuyama S., Kawase M., Nao N. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 // BioRxiv. – 2020. DOI:10.1101/2020.03.11.987016.Matsuyama S., Kawase M., Nao N. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. BioRxiv, 2020. doi:10.1101/2020.03.11.987016.Pennington E. Asthma increases risk of severity of COVID-19 // Cleve Clin. J. Med. ‒ 2020. DOI:10.3949/ccjm.87a.ccc002.Pennington E. Asthma increases risk of severity of COVID-19. Cleve Clin. J. Med., 2020. doi:10.3949/ccjm.87a.ccc002.Peters M. C., Sajuthi S., Deford P. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids // Am. J. Respir. Crit. Care Med. – 2020. – Vol. 202, № 1. – Р. 83-90. DOI: 10.1164/rccm.202003-0821OC.Peters M.C., Sajuthi S., Deford P. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am. J. Respir. Crit. Care Med., 2020, vol. 202, no. 1, pp. 83-90. doi: 10.1164/rccm.202003-0821OC.Riggioni C., Comberiati P., Giovannini M. et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2 // Allergy. – 2020. – Vol. 75, № 5. – Р. 2503-2543. DOI: 10.1111/all.14449.Riggioni C., Comberiati P., Giovannini M. et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy, 2020, vol. 75, no. 5, pp. 2503-2543. doi: 10.1111/all.14449.Sajuthi S. P., DeFord P., Jackson N. D. et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium // Biorxiv. – 2020. DOI: 10.1038/s41467-020-18781-2.Sajuthi S.P., DeFord P., Jackson N.D. et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. Biorxiv, 2020, doi: 10.1038/s41467-020-18781-2.Schleicher G. K., Lowman W., Richards G. A. Case study: a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab // Wits J. Clin. Med. – 2020. – № 2 (SI). ‒ P. 47-52.Schleicher G.K., Lowman W., Richards G.A. Case study: a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab. Wits J. Clin. Med., 2020, no. 2 (SI), pp. 47-52.Shang L., Zhao J., Hu Y. et.al. On the use of corticosteroids for 2019-nCoV pneumonia // Lancet. – 2020. – Vol. 395, № 10225. – Р. 683-684. DOI: 10.1016/S0140-6736(20)30361-5.Shang L., Zhao J., Hu Y. et.al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020, vol. 395, no. 10225, pp. 683-684. doi: 10.1016/S0140-6736(20)30361-5.Starshinova A., Malkova A., Zinchenko U., Kudlay D., Glushkova A., Dovgalyk I., Yablonskiy P., Shoenfeld Y. Efficacy of different types of therapy for COVID-19: A comprehensive review // Life. ‒ 2021. ‒ № 11. ‒ Р. 753. https://doi.org/10.3390/life11080753.Starshinova A., Malkova A., Zinchenko U., Kudlay D., Glushkova A., Dovgalyk I., Yablonskiy P., Shoenfeld Y. Efficacy of different types of therapy for COVID-19: A comprehensive review. Life, 2021, no. 11, pp. 753. https://doi.org/10.3390/life11080753.Vultaggio A., Agache I., Akdis C. A. et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement // Allergy. – 2020. – Vol. 75, № 11. – Р. 2764-2774. DOI: 10.1111/all.14407.Vultaggio A., Agache I., Akdis C.A. et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy, 2020, vol. 75, no. 11, pp. 2764-2774. doi: 10.1111/all.14407.Wan G.-H., Tsai Y.-H., Wu Y.-K., Tsao K.-C. A large-volume nebulizer would not be an infectious source for severe acute respiratory syndrome // Infect. Control. Hosp Epidemiol. – 2004. – Vol. 25, № 12. – Р. 1113-1115. DOI: 10.1086/502353.Wan G.-H., Tsai Y.-H., Wu Y.-K., Tsao K.-C. A large-volume nebulizer would not be an infectious source for severe acute respiratory syndrome. Infect. Control Hosp. Epidemiol., 2004, vol. 25, no. 12, pp. 1113-1115. doi: 10.1086/502353.Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. – 2020. – Vol. 323, № 11. – Р.1061-1069. DOI: 10.1001/jama.2020.1585.Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, vol. 323, no. 11, pp. 1061-1069. doi: 10.1001/jama.2020.1585.Wang Y., Jiang W., He Q. et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China // medRxiv. – 2020. DOI:10.1101/2020.03.06.20032342.Wang Y., Jiang W., He Q. et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv, 2020. doi:10.1101/2020.03.06.20032342.Yamaya M., Nishimura H., Deng X. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells // Respir. Investig. – 2020. – Vol. 58, № 3. – Р. 155-168. DOI: 10.1016/j.resinv.2019.12.005.Yamaya M., Nishimura H., Deng X. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir. Investig., 2020, vol. 58, no. 3, pp. 155-168. doi: 10.1016/j.resinv.2019.12.005.Zhang J. J., Cao Y. Y., Dong X. et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2 // Allergy. – 2020. – Vol. 75, № 7. – Р. 1809-1812. DOI: 10.1111/all.14316.Zhang J.J., Cao Y.Y., Dong X. et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy, 2020, vol. 75, no. 7, pp. 1809-1812. doi: 10.1111/all.14316.Zhang J. J., Dong X., Cao Y. Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China // Allergy. – 2020. – Vol. 75, № 7. – Р. 1730-1741. DOI:10.1111/all.14238.Zhang J.J., Dong X., Cao Y.Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, vol. 75, no. 7, pp. 1730-1741. doi:10.1111/all.14238.Zhang W., Lin C., Sampath V., Nadeau K. Impact of allergen immunotherapy in allergic asthma // Immunotherapy. – 2018. – Vol. 10, № 7. – Р. 579-593. DOI: 10.2217/imt-2017-0138.Zhang W., Lin C., Sampath V., Nadeau K. Impact of allergen immunotherapy in allergic asthma. Immunotherapy, 2018, vol. 10, no. 7, pp. 579-593. doi: 10.2217/imt-2017-0138.Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predisposition with the risk of severe COVID-19 // J. Allergy Clin. Immunol. – 2020. – Vol. 146, № 2. – Р. 327-329.e4. DOI: 10.1016/j.jaci.2020.06.001.Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J. Allergy Clin. Immunol., 2020, vol. 146, no. 2, pp. 327-329.e4. doi: 10.1016/j.jaci.2020.06.001.

The authors declare that there are no conflicts of interest present.